Description
GS9667 is a new selective, partial agonist of the A(1) adenosine receptor (AR). It may be an effective therapy for Type 2 diabetes and dyslipidemia via lowering of free fatty acids (FFA). It was developed by Gilead and was in clinic phase 1 trials without progress